Search:
 

Innovative partnership

The GAVI partnership encompasses many different players. It is an outreach worker from a faith-based organisation biking cold boxes full of chilled vaccines to a remote village in Africa. An international banker holding a video conference on new ways to use capital markets to finance immunisation. A research scientist in a Brazilian vaccine development company working on a formulation that meets the needs of developing countries. A UNICEF social mobilisation expert working with a community nurse to teach mothers about the importance of vaccination at birth. It is top health and development experts gathered in Geneva to evaluate country funding proposals.

Direction

These efforts are directed through the financing mechanisms of the GAVI Fund and the work of the Geneva-based GAVI Secretariat which channel funding, optimise product availability and market pricing, and coordinate the field support necessary to plan and implement programmes in the world’s poorest countries.

Developed country donors, recipient governments, research and technical institutes, civil society organisations, and vaccine industries partner with international organisations, private sector philanthropists and international financiers to find ways to fund and support immunisation in the world’s poorest countries.

An added ingredient has been a strengthening of engagement with civil society organisations. With their reach, experience and knowledge of delivering health and immunisation services on the ground, they bring important resources and perspective to the Alliance and its work. Civil society organisations can also play a very productive role as watchdogs, helping to ensure that government and international actors are accountable to the people and communities they serve.

Public-private effect

Building on public sector expertise in health and development, with the acumen of pivate individuals and organisations, the power of the public-private partnership continues to deliver. GAVI has developed innovative mechanisms and approaches to international health and development such as IFFIm, ADIPs and the pilot AMC. Some of these initiatives have, in turn, sparked the formation of other task-oriented partnerships.

Unique contributions

Partners contribute to the Alliance through participation in strategy and policy-setting, advocacy, fund-raising, vaccine development and procurement, country support and immunisation delivery.

Independent board members also contribute their viewpoints, challenging expectations and the status quo. This dialogue sparks debate and innovation. New balances emerge from testing the boundaries.